Milestone Taking Etripamil Into Phase III For AFib Based On Phase II Success

Approval For PSVT Pending At The US FDA

The company’s calcium channel blocker nasal spray rapidly slowed atrial fibrillation patients’ heart rates, showing potential to be an at-home replacement for emergency room-administered treatment.

Atrial fibrillation medical condition and normal or abnormal heart rate rhythm as a cardiac disorder
Etripamil rapidly slowed ventricular rates in atrial fibrillation patients • Source: Shutterstock

Milestone Pharmaceuticals, Inc.’s inhaled calcium channel blocker etripamil already has shown that it can significantly slow patients’ heart rates in a large Phase III clinical trial as a treatment for paroxysmal supraventricular tachycardia (PSVT). Now, the company plans to initiate a Phase III trial in patients with atrial fibrillation with rapid ventricular rate (AFib-RVR) after the drug was similarly effective at lowering heart rate in the Phase II ReVeRA study of AFib-RVR patients.

Key Takeaways
  • Milestone reported positive Phase II results for its calcium channel blocker etripamil, administered via nasal spray, as a treatment for atrial fibrillation with rapid ventricular rate (AFib-RVR).

Montreal and Charlotte, NC-based Milestone submitted a new drug application for etripamil in the treatment of PSVT to the US...

Welcome to Scrip

Create an account to read this article

More from Clinical Trials

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By 

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

More from R&D

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

Obesity Beyond GLP-1s: Amylins – The Next Frontier

 
• By 

In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.